This site is intended for healthcare professionals
Responding to unmet needs for metastatic castration-resistant prostate cancer
Learning Zone

mCRPC in focus

Last updated:4th Sep 2024
Published:15th Feb 2023

How will emerging clinical trial data impact available treatment strategies for metastatic castration-resistant prostate cancer (mCRPC)? See expert analysis on:

  • Key findings from the mCRPC trials CHAARTED-2, CYCLONE-2, and PSMAfore, with Dr Alexander Chehrazi-Raffle
  • Reasons for the low uptake of guideline recommendations for mCRPC management in practice, with Professor Axel Merseburger
  • The implications of new data presented at 2024 ASCO conferences, in a roundtable discussion with Dr Neeraj Agarwal, Professor Merseburger, Professor Karim Fizazi, and Dr Bárbara Vieira Lima Aguiar Melão
Welcome: